Market cap
$424 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.1
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | 380.78 | 293.30 | 98.47 | 25.66 | 14.58 |
| Net Profit | 358.89 | 278.78 | 93.30 | 24.52 | 13.64 |
| EPS | 353.51 | 273.33 | 92.72 | 24.83 | 14.12 |
| Book Value | -- | -- | -47.48 | -28.12 | -22.84 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -- | -- | -- | -- | -- |
| Net Margin
| -- | -108,377.56 | -- | -- | -- |
| Return on equity
| -54.80 | -49.34 | -5.34 | -60.27 | -54.14 |
| Return on Capital
| -51.84 | -46.56 | -- | -56.43 | -51.42 |
| Return on Assets
| -47.74 | -43.32 | -2.93 | -52.00 | -47.30 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.09 | 0.06 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
-56.43
|
-51.42
|
-47.68
|
-44.83
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-5.34
Higher than Peers by 35.06
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
-5.34
|
-60.27
|
-54.14
|
-50.01
|
-46.98
|
|
Peer Median
|
-40.40
|
--
|
--
|
--
|
--
|
ROA
-2.93
Higher than Peers by 28.05
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
-2.93
|
-52.00
|
-47.30
|
-43.93
|
-42.31
|
|
Peer Median
|
-30.98
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-92.67
|
--
|
--
|
--
|
--
|
EBIT Growth
98.47
Higher than Peers by 99.27
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
98.47
|
13.87
|
-5.39
|
-10.80
|
-34.79
|
|
Peer Median
|
-0.80
|
--
|
--
|
--
|
--
|
Net Profit Growth
93.30
Higher than Peers by 100.60
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
93.30
|
13.77
|
-5.35
|
-10.70
|
-31.23
|
|
Peer Median
|
-7.30
|
--
|
--
|
--
|
--
|
EPS Growth
92.72
Higher than Peers by 78.07
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
92.72
|
0.24
|
0.09
|
0.04
|
-0.16
|
|
Peer Median
|
14.65
|
--
|
--
|
--
|
--
|
Book Value Growth
0.95
Higher than Peers by 11.13
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
0.95
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.18
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
0.09
|
0.06
|
0.05
|
0.05
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.01
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
0.01
|
0.01
|
0.01
|
0.01
|
0.01
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
9.24
Higher than Peers by 3.44
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
9.24
|
6.38
|
9.30
|
7.80
|
9.29
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
9.24
Higher than Peers by 3.55
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
9.24
|
--
|
--
|
--
|
--
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-0.83
Higher than Peers by 1.26
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
-0.83
|
-116.99
|
-136.19
|
-129.98
|
-115.22
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
53.84
|
31.69
|
943.27
|
1,068.48
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
-1.75
|
-4.74
|
-10.25
|
-6.43
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
1.08
Lower than Peers by 4.10
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
1.08
|
1.41
|
2.65
|
5.11
|
2.91
|
|
Peer Median
|
5.18
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
46.63
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
46.63
|
-1.08
|
-3.55
|
-9.17
|
-5.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
424
Higher than Peers by 278
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Rocket Pharmaceuticals (RCKT)
|
424
|
--
|
--
|
--
|
--
|
|
Peer Median
|
146
|
--
|
--
|
--
|
--
|